Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

Blood (2024) 144 (Supplement 1): 607.

https://doi.org/10.1182/blood-2024-200367

Published: 2024

Journal Articles

Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations

Blood (2024) 144 (Supplement 1): 1578.

https://doi.org/10.1182/blood-2024-202951

Published: 2024

Journal Articles

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Blood (2023) 142 (Supplement 1): 295.

https://doi.org/10.1182/blood-2023-173957

Published: 2023

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Blood (2022) 140 (Supplement 1): 4664–4667.

https://doi.org/10.1182/blood-2022-168614

Published: 2022

Journal Articles

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Blood (2022) 140 (Supplement 1): 1770–1772.

https://doi.org/10.1182/blood-2022-159976

Published: 2022

Journal Articles

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Blood (2022) 140 (Supplement 1): 10413–10415.

https://doi.org/10.1182/blood-2022-169037

Published: 2022

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

ULK1 Blockade Preferentially Targets Germinal Centre B-Cell - Diffuse Large B-Cell Lymphoma Subtype By Attenuating Autophagy, c-MYC and Inflammation

Harpreet Mandhair, Ramin Radpour, Andrew Davies, Mario P. Tschan, Urban Novak

Blood (2022) 140 (Supplement 1): 9296–9297.

https://doi.org/10.1182/blood-2022-169004

Published: 2022

Journal Articles

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Joanna Hack, Inês Ralha, Sam Wilding, Louise Stanton, Josh Caddy, Sharon Barrans, Christoph Mamot, Urban Novak, Cathy Burton, Pamela McKay, Gavin Campbell, Andrew Davies, Peter Johnson

Blood (2022) 140 (Supplement 1): 6648–6649.

https://doi.org/10.1182/blood-2022-159442

Published: 2022

Journal Articles

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Blood (2022) 139 (5): 732–747.

https://doi.org/10.1182/blood.2021012386

Published: 2022

Includes: Supplemental data

Journal Articles

Recruitment of NK Cells during Autologous Apheresis Allows Efficient NK Cell Collection for Immunotherapy

Katarzyna Aleksandra Aleksandra Jalowiec, Christoph Bocksrucker, Thomas Pabst, Krzysztof Krasuski, Noel Frey, Ioannis Chanias, Kristina Vrotniakaite-Bajerciene, Urban Novak, Ulrike Bacher, Michael Daskalakis, Behrouz Teleghani Mansouri, Sacha Sergio Zeerleder

Blood (2021) 138 (Supplement 1): 4849.

https://doi.org/10.1182/blood-2021-152652

Published: 2021

Journal Articles

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Barbara Jeker, Sarah Farag, Urban Novak, Ulrike Bacher, Behrouz Mansouri Taleghani, Qiyu Li, Thomas Pabst, MD

Blood (2019) 134 (Supplement_1): 1963.

https://doi.org/10.1182/blood-2019-127848

Published: 2019

Journal Articles

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Blood (2019) 134 (Supplement_1): 353.

https://doi.org/10.1182/blood-2019-129835

Published: 2019

Journal Articles

Rebound Thrombocytosis after Induction Chemotherapy Is a Strong Biomarker for Favorable Outcome in AML Patients

Thomas Pabst, MD, Bianca R Schnell, Ulrike Bacher, Barbara Jeker, Yara Banz, Urban Novak, Katja - Seipel

Blood (2019) 134 (Supplement_1): 5101.

https://doi.org/10.1182/blood-2019-127984

Published: 2019

Journal Articles

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Katarzyna Aleksandra Jalowiec, Thomas Pabst, MD, Christoph Bocksrucker, Claudio Brunold, Barbara Jeker, Gabriela M Baerlocher, MD, Urban Novak, Ulrike Bacher, Michael Daskalakis, MD, Behrouz Mansouri, MD, Sacha S Zeerleder, MD PhD

Blood (2019) 134 (Supplement_1): 2457.

https://doi.org/10.1182/blood-2019-126534

Published: 2019

Journal Articles

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

Thomas Pabst, MD, Sebastian Moser, Ulrike Bacher, Barbara Jeker, Behrouz Mansouri Taleghani, Prof., Urban Novak

Blood (2019) 134 (Supplement_1): 3252.

https://doi.org/10.1182/blood-2019-127940

Published: 2019

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Rudolf A. Benz, MD, Kornelius Arn, MD, Martin Andres, Thomas Pabst, MD PhD, Urban Novak, Felicitas Hitz, MD, Reinhard Zenhäusern, Yves Chalandon, MD PhD, Ulrich Mey, MD, Sabine Blum, Daniel Rauch, Willy Nettekoven, Nathan Cantoni, MD, Mario Bargetzi, MD, Alix O'Meara, MD, Andreas Lohri, MD, Simona Berardi, PhD BSc, Qiyu Li, Georg Stussi, MD

Blood (2018) 132 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2018-99-114301

Published: 2018

NARROW

Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

ULK1 Blockade Preferentially Targets Germinal Centre B-Cell - Diffuse Large B-Cell Lymphoma Subtype By Attenuating Autophagy, c-MYC and Inflammation

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Recruitment of NK Cells during Autologous Apheresis Allows Efficient NK Cell Collection for Immunotherapy

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Rebound Thrombocytosis after Induction Chemotherapy Is a Strong Biomarker for Favorable Outcome in AML Patients

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only